168 related articles for article (PubMed ID: 38233388)
1. Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies.
Estévez-Paredes M; Mata-Martín MC; de Andrés F; LLerena A
Pharmacogenomics J; 2024 Jan; 24(1):2. PubMed ID: 38233388
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
5. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels.
Deb S; Hopefl R; Reeves AA; Cvetkovic D
Medicines (Basel); 2024 Feb; 11(3):. PubMed ID: 38535119
[TBL] [Abstract][Full Text] [Related]
6. Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and its Ethical Implications.
Güner MD; Ekmekci PE; Kurtoglu B
Curr Drug Saf; 2022; 17(1):47-53. PubMed ID: 34315387
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
[TBL] [Abstract][Full Text] [Related]
10. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Vivot A; Boutron I; Ravaud P; Porcher R
Genet Med; 2015 Sep; 17(9):733-8. PubMed ID: 25521333
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
Cheng CM; So TW; Bubp JL
Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
[TBL] [Abstract][Full Text] [Related]
14. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
[TBL] [Abstract][Full Text] [Related]
17. Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.
Faruque F; Noh H; Hussain A; Neuberger E; Onukwugha E
J Manag Care Spec Pharm; 2019 Feb; 25(2):260-271. PubMed ID: 30698084
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).
Kim JA; Ceccarelli R; Lu CY
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33806453
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
20. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
Hafner S; Haubensak S; Paul T; Zolk O
Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
